Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: RNA interference-based therapeutics - Dharmacon/University of Massachusetts Medical School

Drug Profile

Research programme: RNA interference-based therapeutics - Dharmacon/University of Massachusetts Medical School

Latest Information Update: 02 May 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dharmacon; University of Massachusetts Medical School
  • Class Small interfering RNA
  • Mechanism of Action Genetic transcription inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetes mellitus; Obesity

Most Recent Events

  • 06 Apr 2004 Dharmacon has been acquired by Fisher Scientific International
  • 16 Jan 2004 Preclinical trials in Diabetes mellitus in USA (unspecified route)
  • 16 Jan 2004 Preclinical trials in Obesity in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top